GlaxoSmithKline/£GSK
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About GlaxoSmithKline
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Ticker
£GSK
Sector
Primary listing
LSE
Employees
68,629
Headquarters
Website
GlaxoSmithKline Metrics
BasicAdvanced
£59B
17.83
£0.83
0.29
£0.62
4.21%
Price and volume
Market cap
£59B
Beta
0.29
52-week high
£15.96
52-week low
£12.43
Average daily volume
6.9M
Dividend rate
£0.62
Financial strength
Current ratio
0.867
Quick ratio
0.555
Long term debt to equity
106.618
Total debt to equity
120.9
Dividend payout ratio (TTM)
72.80%
Interest coverage (TTM)
10.25%
Profitability
EBITDA (TTM)
9,291
Gross margin (TTM)
71.69%
Net profit margin (TTM)
10.82%
Operating margin (TTM)
20.13%
Effective tax rate (TTM)
13.80%
Revenue per employee (TTM)
£460,000
Management effectiveness
Return on assets (TTM)
6.78%
Return on equity (TTM)
28.33%
Valuation
Price to earnings (TTM)
17.828
Price to revenue (TTM)
1.899
Price to book
4.03
Price to tangible book (TTM)
-8.15
Price to free cash flow (TTM)
12.398
Free cash flow yield (TTM)
8.07%
Free cash flow per share (TTM)
1.188
Dividend yield (TTM)
4.21%
Growth
Revenue change (TTM)
0.59%
Earnings per share change (TTM)
-15.48%
3-year revenue growth (CAGR)
4.37%
10-year revenue growth (CAGR)
3.09%
3-year earnings per share growth (CAGR)
-9.68%
10-year earnings per share growth (CAGR)
-10.43%
3-year dividend per share growth (CAGR)
-9.94%
10-year dividend per share growth (CAGR)
-4.52%
What the Analysts think about GlaxoSmithKline
Analyst ratings (Buy, Hold, Sell) for GlaxoSmithKline stock.
Bulls say / Bears say
GSK expects full-year 2025 sales and profit at the top end of its 3–5% revenue growth and 6–8% EPS guidance after reporting Q2 sales of £7.99 billion and adjusted EPS of 46.5 pence, both beating analyst forecasts (Reuters)
The £2 billion share buyback launched after Q4 2024 results, combined with a revised long-term sales target near $50 billion, underscores management’s confidence in GSK’s growth drivers (Reuters)
U.S. CDC’s July 2025 acceptance of ACIP recommendations expanded use of GSK’s Arexvy RSV vaccine to adults aged 50–59, broadening the addressable market for a product with proven two-season protection (Reuters)
FDA advisory panel’s recommendation against approving Blenrep is likely to delay U.S. market entry and jeopardize up to £3 billion in peak sales forecasts, straining GSK’s pipeline growth (Reuters)
Uncertainty over U.S. vaccination policy under new HHS leadership could hamper uptake of Arexvy RSV vaccine, exposing GSK to revenue volatility in its largest market (Reuters)
GSK forecasts a low single-digit decline in vaccine sales for 2025, reflecting ongoing headwinds in its largest division and pressuring overall revenue growth (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.
GlaxoSmithKline Financial Performance
Revenues and expenses
GlaxoSmithKline Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
Oct9
GlaxoSmithKline
DividendPayment
£0.16Per share
FAQs
What’s the current market cap for GlaxoSmithKline stock?
GlaxoSmithKline (GSK) has a market cap of £59B as of September 19, 2025.
What is the P/E ratio for GlaxoSmithKline stock?
The price to earnings (P/E) ratio for GlaxoSmithKline (GSK) stock is 17.83 as of September 19, 2025.
Does GlaxoSmithKline stock pay dividends?
Yes, the GlaxoSmithKline (GSK) stock pays dividends to shareholders. As of September 19, 2025, the dividend rate is £0.62 and the yield is 4.21%. GlaxoSmithKline has a payout ratio of 72.8% on a trailing twelve-month basis.
When is the next GlaxoSmithKline dividend payment date?
The next GlaxoSmithKline (GSK) dividend payment is scheduled for October 09, 2025.
What is the beta indicator for GlaxoSmithKline?
GlaxoSmithKline (GSK) has a beta rating of 0.29. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.